RT Journal Article
SR Electronic
T1 DRUL for School: Opening Pre-K with safe, simple, sensitive saliva testing for SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.03.21254873
DO 10.1101/2021.04.03.21254873
A1 Frank, Mayu O.
A1 Blachere, Nathalie E.
A1 Parveen, Salina
A1 Hacisuleyman, Ezgi
A1 Fak, John
A1 Luna, Joseph M.
A1 Michailidis, Eleftherios
A1 Wright, Samara
A1 Stark, Pamela
A1 Campbell, Ann
A1 Foo, Ashley
A1 Sakmar, Thomas P.
A1 Huffman, Virginia
A1 Bergh, Marissa
A1 Goldfarb, Audrey
A1 Mansisidor, Andres
A1 Patriotis, Agata L.
A1 Palmquist, Karl H.
A1 Poulton, Nicolas
A1 Leicher, Rachel
A1 Vargas, César D. M.
A1 Duba, Irene
A1 Hurley, Arlene
A1 Colagreco, Joseph
A1 Pagane, Nicole
A1 Orange, Dana E.
A1 Mora, Kevin
A1 Rakeman, Jennifer L.
A1 Fowler, Randall C.
A1 Fernandes, Helen
A1 Lamendola-Essel, Michelle F.
A1 Didkovsky, Nick
A1 Silvera, Leopolda
A1 Masci, Joseph
A1 Allen, Machelle
A1 Rice, Charles M.
A1 Darnell, Robert B.
YR 2021
UL http://medrxiv.org/content/early/2021/04/06/2021.04.03.21254873.abstract
AB To address the need for simple, safe, sensitive, and scalable SARS-CoV-2 tests, we validated and implemented a PCR test that uses a saliva collection kit use at home. Individuals self-collected 300 µl saliva in vials containing Darnell Rockefeller University Laboratory (DRUL) buffer and extracted RNA was assayed by RT-PCR (the DRUL saliva assay). The limit of detection was confirmed to be 1 viral copy/µl in 20 of 20 replicate extractions. Viral RNA was stable in DRUL buffer at room temperature up to seven days after sample collection, and safety studies demonstrated that DRUL buffer immediately inactivated virus at concentrations up to 2.75×106 PFU/ml. Results from SARS-CoV-2 positive nasopharyngeal (NP) swab samples collected in viral transport media and assayed with a standard FDA Emergency Use Authorization (EUA) test were highly correlated with samples placed in DRUL buffer. Direct comparison of results from 162 individuals tested by FDA EUA oropharyngeal (OP) or NP swabs with co-collected saliva samples identified four otherwise unidentified positive cases in DRUL buffer. Over six months, we collected 3,724 samples from individuals ranging from 3 months to 92 years of age. This included collecting weekly samples over 10 weeks from teachers, children, and parents from a pre-school program, which allowed its safe reopening while at-risk pods were quarantined. In sum, we validated a simple, sensitive, stable, and safe PCR-based test using a self-collected saliva sample as a valuable tool for clinical diagnosis and screening at workplaces and schools.Competing Interest StatementR.B.D. wishes to disclose that he receives consulting fees as a Senior Visiting Fellow at MITRE Corporation, has started a charitable LLC, D4S Testing, to offer free DRUL saliva testing to NYC school children, and is an Investigator of the Howard Hughes Medical Institute.Funding StatementC.M.R acknowledges the generous support of the G. Harold and Leila Y. Mathers Charitable Foundation, the BAWD Foundation, and The Rockefeller University. R.B.D. is an Investigator of the Howard Hughes Medical Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Protocols for the collection of saliva samples were either approved by the Rockefeller University (RU) Institutional Review Board (IRB) and Biomedical Research Alliance of New York IRB or were deemed not to be human subjects research by the RU IRB. Where required, written or verbal consent was obtained from all volunteers.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data in this manuscript is available upon request.